LTFS
BMRN icon

Ladenburg Thalmann Financial Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$360K Buy
4,344
+370
+9% +$27.9K ﹤0.01% 2071
2019
Q3 		$267K Buy
3,974
+88
+2% +$6.78K ﹤0.01% 2255
2019
Q2 		$335K Sell
3,886
-4,502
-54% -$385K ﹤0.01% 2057
2019
Q1 		$745K Buy
8,388
+692
+9% +$64.1K 0.01% 1385
2018
Q4 		$659K Buy
7,696
+3,546
+85% +$337K 0.01% 1339
2018
Q3 		$402K Buy
4,150
+472
+13% +$47.1K ﹤0.01% 1776
2018
Q2 		$299K Hold
3,678
– – ﹤0.01% 1934
2018
Q1 		$299K Buy
3,678
+454
+14% +$39K ﹤0.01% 1934
2017
Q4 		$287K Buy
3,224
+600
+23% +$52.2K ﹤0.01% 1925
2017
Q3 		$244K Buy
2,624
+39
+2% +$3.45K ﹤0.01% 1955
2017
Q2 		$235K Sell
2,585
-141
-5% -$12.8K ﹤0.01% 1899
2017
Q1 		$239K Buy
2,726
+139
+5% +$12.4K ﹤0.01% 1788
2016
Q4 		$215K Sell
2,587
-18
-0.7% -$1.55K ﹤0.01% 1775
2016
Q3 		$241K Sell
2,605
-53
-2% -$4.99K ﹤0.01% 1628
2016
Q2 		$207K Buy
2,658
+213
+9% +$18.1K ﹤0.01% 1657
2016
Q1 		$202K Buy
2,445
+450
+23% +$36.6K ﹤0.01% 1601
2015
Q4 		$209K Sell
1,995
-378
-16% -$39.5K ﹤0.01% 1550
2015
Q3 		$250K Sell
2,373
-328
-12% -$43.8K 0.01% 1333
2015
Q2 		$370K Buy
2,701
+600
+29% +$74.4K 0.01% 1212
2015
Q1 		$261K Sell
2,101
-413
-16% -$43.8K 0.01% 1396
2014
Q4 		$227K Sell
2,514
-513
-17% -$42.7K 0.01% 1335
2014
Q3 		$218K Buy
3,027
+1,760
+139% +$116K 0.01% 1174
2014
Q2 		$79K Buy
1,267
+311
+33% +$18.8K ﹤0.01% 1742
2014
Q1 		$65K Sell
956
-70
-7% -$5.16K ﹤0.01% 1771
2013
Q4 		$72K Buy
1,026
+28
+3% +$1.9K ﹤0.01% 1667
2013
Q3 		$71K Buy
998
+78
+8% +$5.18K ﹤0.01% 1590
2013
Q2 		$53K Buy
+920
New +$57.3K ﹤0.01% 1701

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ladenburg Thalmann Financial Services's BMRN Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its BioMarin Pharmaceuticals (BMRN) stake by 9.3% in Q4 2019, buying an estimated $27.9K and bringing the position to 4,344 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #2071.

Ladenburg Thalmann Financial Services first reported a position in BMRN in Q2 2013 and has held it in 27 quarters since. The position peaked at $745K in Q1 2019. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 4,344 shares of BioMarin Pharmaceuticals worth $360K as of Q4 2019.
  • Ladenburg Thalmann Financial Services bought 370 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $27.9K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #2071 holding.
  • Ladenburg Thalmann Financial Services first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • Ladenburg Thalmann Financial Services's BioMarin Pharmaceuticals position peaked at $745K in Q1 2019.
  • 467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.